Mirikizumab helped patients with Crohn’s Disease achieve long-term remission in Phase 3 trial.
Eli Lilly and Company announced today that mirikizumab (an investigational interleukin-23p19 antagonist) met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of…